Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings
August 13, 2024 2:57 PM EDTCantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD).
The analyst comments "We reiterate our Overweight rating and 12-month price target of $3.00 on Lucid Diagnostics' (LUCD) shares following the company reporting 2Q24 operating results and providing... More
Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS
August 12, 2024 9:47 AM EDTLucid Diagnostics Inc. (NASDAQ: LUCD) reported Q2 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $980 thousand versus the consensus estimate of $1.22 million.
For earnings history and earnings-related data on Lucid Diagnostics Inc. (LUCD) click here.
... More